Clinical trials: Respiratory Distress Syndrome, Adult
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
Acute Respiratory Distress Syndrome, Shock
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
The objective of our study is to evaluate the efficacy of helmet ventilation as compared with Face mask in patients with respiratory failure.
- Conditions
- Acute Respiratory Distress Syndrome, Shock, Ventilatory Failure, Cardiogenic Pulmonary Edema
- Trial name
- NCT01680783
- Testing
- Non invasive ventilation using a helmet hyperbaric device, Noninvasive ventilation via facemask
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Chicago
Respiratory Distress Syndrome in Premature Infants, Very Low Birth Weight Baby
Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation
This study hopes to determine whether nitric oxide along with oxygen during the first 20 minutes of life in infants needing help with breathing will reduce the percentage and total exposure to oxygen during that time frame.
- Trial name
- iNO (NCT01220687)
- Testing
- iNO, Nitrogen
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Oklahoma
Acute Lung Injury
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute lung injury (ALI) is a common, life-threatening complication among pediatric leukemia and lymphoma and hematopoietic stem cell transplant (HSCT) recipients.
- Trial name
- CALIPSO (NCT00999713)
- Testing
- Calfactant
- Where
- 16 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Milton S. Hershey Medical Center
Lung Injury, Acute and Respiratory Distress Syndrome, Adult
Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery
Lung injury in patients undergoing oesophagectomy may occur during surgery (peri-operatively) as a result of One Lung Ventilation (OLV) and/or during the immediate post-operative period when patients receive intensive care.
- Trial name
- NCT02221037
- Testing
- GSK2862277
- Where
- 6 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
- Trial name
- NCT04389671
- Testing
- Lucinactant
- Where
- 11 sites in United States, Argentina
- Volunteers
- 20 people
- Sponsor
- Windtree Therapeutics
COVID-19
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
- Trial name
- PREVENT (NCT04365257)
- Testing
- Prazosin, Standard of care
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Respiratory Distress Syndrome, Adult
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in…
- Trial name
- START (NCT02097641)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Michael A. Matthay
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
- Trial name
- NCT00626028
- Testing
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Where
- 18 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- Mallinckrodt
ARDS, Covid19
Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)
Prone positioning is one of the few therapies known to improve mortality in ARDS. Traditionally, patients are proned for 16 hours per 24 hour period. Some retrospective data suggests improvement may persist beyond 16 hours.
- Conditions
- ARDS, Covid19, Acute Hypoxemic Respiratory Failure
- Trial name
- NCT04581811
- Testing
- Prolonged Proned Positioning, Traditional Proning Arm
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Alabama at Birmingham
Acute Respiratory Distress Syndrome
LIPS-A: Lung Injury Prevention Study With Aspirin
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
- Trial name
- NCT01504867
- Testing
- Aspirin, Lactose powder
- Where
- 16 sites in United States
- Volunteers
- 400 people
- Sponsor
- Mayo Clinic
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Acute Respiratory Distress Syndrome, Vitamin D Deficiency
Vitamin D to Improve Outcomes by Leveraging Early Treatment
Vitamin D deficiency is a common, potentially reversible contributor to morbidity and mortality among critically ill patients. We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D3…
- Conditions
- Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
- Trial name
- VIOLET (NCT03096314)
- Testing
- Vitamin D3
- Where
- 47 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Massachusetts General Hospital
Respiratory Distress Syndrome, Adult, Sepsis
Early Insulin and Development of ARDS
Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Symptoms usually develop within 24 to 48 hours of an original injury or illness, and people with…
- Conditions
- Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
- Trial name
- NCT00605696
- Testing
- Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
Respiratory Distress Syndrome
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks…
- Trial name
- NCT02074059
- Testing
- Lucinactant for Inhalation, nCPAP alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Windtree Therapeutics
Respiratory Distress Syndrome, Newborn
A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age
This study is to evaluate the safety and efficacy of lucinactant for inhalation in conjunction with nCPAP, in comparison to nCPAP alone, in preterm neonates with RDS, as assessed by the incidence of and time to respiratory…
- Trial name
- NCT04264156
- Testing
- Lucinactant for Inhalation, nCPAP Only
- Where
- 3 sites in Poland
- Volunteers
- 12 people
- Sponsor
- Windtree Therapeutics
Respiratory Distress Syndrome
Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
Premature infants frequently have trouble breathing after birth. If the respiratory disorder is caused by surfactant deficiency or dysfunction, the disease is treated with a medication called surfactant that is given to the…
- Trial name
- NEOSURF (NCT02834624)
- Testing
- Poractant alfa, calfactant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Missouri-Columbia
Respiratory Distress Syndrome
Comparative Effectiveness Study of Bubble CPAP Devices in the NICU
Multiple different devices are available to provide Bubble CPAP to preterm and newborn infants. The most significant difference between these devices is the size of the bubble produced by the exhalation limb.
- Trial name
- NCT02392806
- Testing
- Bubble CPAP- BabiPlus, Respiralogics, Bubble CPAP- B&B Bubbler, B&B Medical devices
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Marya Strand, MD
Wounds and Injuries, Venous Thromboembolism
STAT-STatin and Aspirin in Trauma
This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with…
- Trial name
- STAT (NCT02901067)
- Testing
- Aspirin and Rosuvastatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Denver Health and Hospital Authority